Evidence map›Paper›PMID 38877340›Full record

ReviewDiscover oncology2024

The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma.

Long-Ying Zhu, Qi-Lei Hu, Liang Zhang, Zuo-Jie Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Long-Ying ZhuSchool of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, People's Republic of China.
Qi-Lei HuDepartment of Clinical Laboratory, First People's Hospital of Linping District, Hangzhou, 311100, Zhejiang, People's Republic of China.
Liang ZhangDepartment of Clinical Laboratory, First People's Hospital of Linping District, Hangzhou, 311100, Zhejiang, People's Republic of China.
Zuo-Jie LiDepartment of Clinical Laboratory, The People's Hospital of Cangnan Zhejiang, No. 2288 Yucang Road, Cangnan County, Wenzhou, Zhejiang, 325800, People's Republic of China. lizuojie_li@126.com.

Funding

Basic Scientific Research Projects of Wenzhou Science and Technology Bureau No.Y20210747Medicine and Health Science and Technology Plan Projects in Zhejiang Province No. 2024XY044
6 · The paper itself

Abstract

Multiple myeloma (MM) denotes a cancerous growth characterized by abnormal proliferation of plasma cells. Growing evidence suggests that the complexity in addressing MM lies in the presence of minimal residual disease (MRD) within the body. MRD assessment is becoming increasingly important for risk assessment in patients with MM. Similarly, the levels of serum free protein light chain and their ratio play a crucial role in assessing the disease burden and changes in MM. In this paper, we review and explore the utilization of MRD and serum free light chain ratio in the treatment of MM, delving into their respective characteristics, advantages, disadvantages, and their interrelation.

Indexed as

Duration of Response (DOR)Minimal residual disease (MRD)Multiple myeloma (MM)Serum free light chain ratio (sFLCR)Stringent complete response (sCR)

Identifiers

PMID38877340
PMCPMC11178694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.